Arrowhead Pharma Financials - Benzinga

Arrowhead Pharmaceuticals Inc

ARWRNASDAQ

Trade with Public

Trade with Public

$65.97

-0.99-1.48%

마지막 업데이트: Sep 24, 1:00 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Arrowhead Pharma Financials

Arrowhead Pharma (ARWR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from

Benzinga Newsdesk

PRO
Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst consensus estimate of $(1.14) by 18.42 percent. This is a 133.82 percent decrease over earnings of $2.75 per share from

Benzinga Newsdesk

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.

Vandana Singh

Arrowhead Pharma Q1 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Arrowhead Pharma Q1 EPS $0.22 Beats $0.14 Estimate, Sales $264.033M Miss $270.066M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 59.42 percent. This is a 115.83 percent increase over losses of $(1.39) per share from

Benzinga Newsdesk

Earnings Scheduled For February 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved